These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 20531184)

  • 1. Lipoprotein subfractions and cardiovascular disease risk.
    Krauss RM
    Curr Opin Lipidol; 2010 Aug; 21(4):305-11. PubMed ID: 20531184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should we routinely measure low-density and high-density lipoprotein subclasses?
    Rizzo M; Berneis K; Zeljkovic A; Vekic J
    Clin Lab; 2009; 55(11-12):421-9. PubMed ID: 20225664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormone therapy, lipoprotein subclasses, and coronary calcification: the Healthy Women Study.
    Mackey RH; Kuller LH; Sutton-Tyrrell K; Evans RW; Holubkov R; Matthews KA
    Arch Intern Med; 2005 Mar; 165(5):510-5. PubMed ID: 15767525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small dense low-density lipoprotein and its role as an independent predictor of cardiovascular disease.
    Packard CJ
    Curr Opin Lipidol; 2006 Aug; 17(4):412-7. PubMed ID: 16832165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atherosclerotic risk factors in cardiovascular disease.
    LaRosa JC
    J Reprod Med; 1986 Sep; 31(9 Suppl):906-12. PubMed ID: 3772910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial.
    Otvos JD; Collins D; Freedman DS; Shalaurova I; Schaefer EJ; McNamara JR; Bloomfield HE; Robins SJ
    Circulation; 2006 Mar; 113(12):1556-63. PubMed ID: 16534013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of oral contraceptives on lipid metabolism.
    Krauss RM
    J Reprod Med; 1986 Jun; 31(6 Suppl):549-50. PubMed ID: 3723487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-density lipoprotein size and cardiovascular risk assessment.
    Rizzo M; Berneis K
    QJM; 2006 Jan; 99(1):1-14. PubMed ID: 16371404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distribution of low-density lipoprotein and high-density lipoprotein subclasses in patients with sarcoidosis.
    Vekic J; Zeljkovic A; Jelic-Ivanovic Z; Spasojevic-Kalimanovska V; Spasic S; Videnovic-Ivanov J; Ivanisevic J; Vucinic-Mihailovic V; Gojkovic T
    Arch Pathol Lab Med; 2013 Dec; 137(12):1780-7. PubMed ID: 24283859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma lipoprotein levels as predictors of cardiovascular death in women.
    Bass KM; Newschaffer CJ; Klag MJ; Bush TL
    Arch Intern Med; 1993 Oct; 153(19):2209-16. PubMed ID: 8215724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should we measure routinely the LDL peak particle size?
    Rizzo M; Berneis K
    Int J Cardiol; 2006 Feb; 107(2):166-70. PubMed ID: 16412793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid and lipoprotein metabolism in chronic kidney disease.
    Kaysen GA
    J Ren Nutr; 2009 Jan; 19(1):73-7. PubMed ID: 19121776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small, dense low-density-lipoproteins and the metabolic syndrome.
    Rizzo M; Berneis K
    Diabetes Metab Res Rev; 2007 Jan; 23(1):14-20. PubMed ID: 17080469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease.
    Mudd JO; Borlaug BA; Johnston PV; Kral BG; Rouf R; Blumenthal RS; Kwiterovich PO
    J Am Coll Cardiol; 2007 Oct; 50(18):1735-41. PubMed ID: 17964036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Postprandial hyperlipidemia, small and dense LDL, HDL sub-fractions].
    Braschi S
    Ann Med Interne (Paris); 2001 Apr; 152(3):162-8. PubMed ID: 11431575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Women, lipoproteins and cardiovascular disease risk.
    LaRosa JC
    Can J Cardiol; 1990 May; 6 Suppl B():23B-29B. PubMed ID: 2188715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
    Fabbri G; Maggioni AP
    Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inverse correlation of serum paraoxonase and homocysteine thiolactonase activities and antioxidant capacity of high-density lipoprotein with the severity of cardiovascular disease in persons with type 2 diabetes mellitus.
    Lakshman MR; Gottipati CS; Narasimhan SJ; Munoz J; Marmillot P; Nylen ES
    Metabolism; 2006 Sep; 55(9):1201-6. PubMed ID: 16919539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy.
    Jeyarajah EJ; Cromwell WC; Otvos JD
    Clin Lab Med; 2006 Dec; 26(4):847-70. PubMed ID: 17110242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LDL and HDL subclasses and their relationship with Framingham risk score in middle-aged Serbian population.
    Vekic J; Topic A; Zeljkovic A; Jelic-Ivanovic Z; Spasojevic-Kalimanovska V
    Clin Biochem; 2007 Mar; 40(5-6):310-6. PubMed ID: 17291473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.